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Abstract
Background: The purpose of this study was to compare the expression and the prognostic effect of the breast
cancer stem cell marker aldehyde dehydrogenase-1 (ALDH1) in young and elderly breast cancer patients.
Methods: The study population (N = 574) consisted of all early breast cancer patients primarily treated with
surgery in our center between 1985 and 1994. Median follow-up was 17.9 years (range: 0.1 to 23.5). Tissue
microarray slides were immunohistochemically stained for ALDH1 expression and quantified by two independent
observers who were blinded to clinical outcome. Assessment of the prognostic effect of ALDH1 expression was
stratified according to age and systemic treatment.
Results: Complete lack of expression of ALDH1 was found in 40% of tumors. With increasing age more tumors
showed complete absence of ALDH1 expression (P < .001). In patients aged > 65 years, ALDH1 status was not
associated with any clinical outcome. Conversely, in patients aged < 65 years, ALDH1 positivity was an
independent risk factor of worse outcome for relapse free period (hazard ratio = 1.71 (95% CI, 1.09 to 2.68); P =
.021) and relative survival (relative excess risks of death = 2.36 (95% CI, 1.22 to 3.68); P = .016). Ten-year relative
survival risk was 57% in ALDH1-positive patients compared to 83% in ALDH1-negative patients.
Conclusion: ALDH1 expression and its prognostic effect are age-dependent. Our results support the hypothesis
that breast cancer biology is different in elderly patients compared to their younger counterparts and emphasizes
the importance of taking into consideration age-specific interactions in breast cancer research.
Keywords: Breast cancer, Age, ALDH1, Prognostic factor Part of this work has been presented at the American
Association for Cancer Research (AACR) Annual Meeting 2011
Background
Age at diagnosis of breast cancer is an important inde-
pendent prognostic factor. Young age is associated with
more aggressive tumors with a relatively high risk of dis-
tant metastasis and loco-regional recurrence [1],
whereas old age is associated with more indolent tumors
[2,3]. Although tumor characteristics differ considerably
between age groups (including hormone receptor and
human epidermal growth factor receptor 2 (HER2)
status), these tumor characteristics can only account for
part of the divergence in survival witnessed between age
groups [3]. Little is known about the impact and signifi-
cance of various prognostic and predictive factors in
elderly as compared to their younger counterparts. As is
the case with randomized trials, elderly are underrepre-
sented in translational studies on molecular markers
[4,5]. This caveat is especially worrisome since studies
show that the relative survival in elderly breast cancer
patient is lower, despite more favorable tumor charac-
teristics, which is probably due to the fact that these
patients receive less aggressive treatment [6]. Molecular
markers could aid to guide therapy in the fit elderly.
Moreover, specific age-interactions might underlie
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mary breast cancer and subsequent local and distant
metastases. Therefore, breast cancer researchers should
account for age-specific differences [5].
Recent evidence in tumor biology supports the cancer
stem cell theory and may also provide a biological rea-
son for the age-associated survival difference [7].
According to this theory, cancer stem cells, defined as a
small subset of tumor cells with stem cell-like features
including epithelial-to-mesenchymal transition, have the
capacity to self-renewal and differentiation, giving rise to
heterogeneous tumor cell population. Various putative
markers of breast cancer stem cells have been proposed,
including aldehyde dehydrogenase-1 (ALDH1) activity,
CD44+/CD24-, CD133, and ITGA6 [7-10]. In particular,
ALDH1 expression has shown promise as a clinically
relevant prognostic marker [9,11,12]. Moreover, various
studies have shown that the subset of cancer stem cells
is relatively resistant to chemo- and radiotherapy
[13,14]. Thereby, the subpopulation of cancer stem cells
can provide both an explanation and a therapeutic tar-
get for poor-prognostic, treatment-resistant and recur-
rent breast cancer.
ALDH1 is a detoxifying enzyme responsible for the
oxidation of intracellular aldehydes and thereby confers
resistance to alkylating agents [12,15]. This detoxifying
capacity might underlie the longevity of stem cells by
protecting against oxidative stress. Moreover, ALDH1
may have a role in early differentiation of stem cells and
stem cell proliferation through its role in oxidizing reti-
nol to retinoic acid, a modulator of cell proliferation
[15]. ALDH1 expression is associated with unfavorable
tumor characteristics in breast cancer, such as high
grade, absence of hormone receptor expression, positive
HER2 status and the basal-like molecular subtype
[9,16-18].
To study whether the expression of the breast cancer
stem cell marker ALDH1 is associated with age and has
an influence on clinical outcome, we analyzed the age-
distribution of ALDH1 expression and its prognostic
role in young and elderly patients using long-term fol-
low-up data of a cohort of breast cancer patients pri-
marily treated with surgery in our institution.
Methods
Study cohort
The patient population comprised all non-metastasized
breast cancer patients primarily treated with surgery in
the Leiden University Medical Center between 1985 and
1994 with tumor material available (N = 574) [19].
Patients with bilateral tumors or a prior history of can-
cer (other than basal cell carcinoma or cervical carci-
noma in situ) were excluded. The following data were
known: age, tumor grade, histological type, TNM stage,
local and systemic therapy, locoregional or distant
tumor recurrence, survival, and expression of estrogen
receptor (ER), progesterone receptor (PgR) and human
epidermal growth factor receptor 2 (HER2). All tumors
were graded according to current pathological standards
by an experienced breast cancer pathologist (V.S.). Med-
ian follow-up was 17.9 years (range: 0.01 to 23.5).
Approval was obtained from the Leiden University Med-
ical Center Medical Ethics Committee. All samples were
handled in a coded fashion, according to National ethi-
cal guidelines ("Code for Proper Secondary Use of
Human Tissue”, Dutch Federation of Medical Scientific
Societies).
Assessment of ALDH1 expression
Mouse antibody against ALDH1A1 (611195, BD Bios-
ciences) was used for immunohistochemistry. Tissue
sections of 4 μm were cut from a previously constructed
tissue microarray of formalin-fixed paraffin-embedded
tumors of 574 patients from whom tumor material was
available [19]. Immunohistochemical staining was per-
formed according to previously described standard pro-
tocols [19]. Human liver tissue slides served as positive
control. Negative controls were human liver tissue slides
that did undergo the whole immunohistochemical stain-
ing without primary antibodies. Microscopic analysis of
ALDH1 was assessed independently by two observers in
a blinded manner. Absence and presence of ALDH1
activity was classified as 0% and 1-100% staining of
tumor cells, respectively (Figure 1A), as was used by
others [9,11].
Statistical analysis
Statistical analyses were performed using the statistical
packages SPSS (version 16.0 for Windows, Spps Inc,
Chicago, IL, USA) and Stata (version 10.0 for Windows,
StataCorp, College Station, TX, USA). Cohen’sk a p p a
coefficient was used to assess the inter-observer agree-
ment in quantification of ALDH1 expression. The
Cohen’s kappa coefficient was 0.81. The c
2 test was
used to evaluate associations between various clinico-
pathological parameters and ALDH1 expression.
Relapse-free period was defined as the time from date of
surgery until an event (locoregional recurrence and/or a
distance recurrence, whichever came first). Relapse-free
period is reported as cumulative incidence function,
after accounting for death as competing risk [20]. The
Kaplan-Meier method was used for survival plotting and
log-rank test for comparison of relapse-free period
curves. Cox proportional hazard analysis was used for
univariate and multivariable analysis for relapse-free per-
iod. Relative survival was calculated by the Hakulinen
method as the ratio of the survival observed among the
cancer patients and the survival that would have been
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year) general population. National life tables were used
to estimate expected survival. Relative excess risks of
death were estimated using a multivariable generalized
linear model with a Poisson distribution, based on col-
lapsed relative survival data, using exact survival times.
Analyses were performed for all patients and stratified
for age and systemic treatment. Age of 65 years at time of
diagnosis was chosen as the cut-off point for age stratifica-
tion [21]. An interaction term with age and ALDH1 status
was introduced in Cox proportional hazard model to
assess the interaction in prognostic effects of ALDH1 sta-
tus for the age groups. Variables with a P-value of < .10 in
univariate analysis were entered in multivariable analysis.
Results
ALDH1 expression in patient cohort
Immunohistochemical data of ALDH1 expression were
available for 496 of the 574 patients (86.4%). Of these
patients, 326 (65.7%) were < 65 years at diagnosis and
170 (34.3%) were > 65 years at diagnosis. The Cohen’s
kappa coefficient for inter-observer agreement was 0.81.
C o m p l e t el a c ko fe x p r e s s i o no fA L D H 1o fa n yt u m o r
cell was found in 40.4% of the tumors. The association
between ALDH1 status and age is shown in Figure 1B.
ALDH1 expression was inversely correlated with age (P
= .0015) and was significantly higher in patients aged <
65 years (65.3%) than in patients aged > 65 years
(48.2%; P < .001). The association of ALDH1 expression
A 
B 
logistic regression p = 0.015 
ALDH-1 absence 
ALDH-1 presence 
Figure 1 ALDH1 expression and distribution over age groups. A. Representative photographs of tissue microarray punches of human breast
cancer specimens immunohistochemically stained for ALDH1 with representative examples of no staining (left panel), intermediate staining
(middle panel) and strong staining (right panel). Bar represents 100 μm. B. ALDH1 status according to age (N = 496). Logistic regression P-value
is shown.
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is shown in Table 1. In patients aged < 65 years,
ALDH1 expression was significantly correlated with
high histological grade and positive nodal status. In
patients aged > 65 years, ALDH1 expression was signifi-
cantly correlated with absence of estrogen-receptor
expression.
Impact of ALDH1 on survival
The association of ALDH1 status with relapse-free per-
iod and relative survival is shown in Figures 2 and 3,
respectively. Analysis of relapse-free period showed a
trend towards a significant association between ALDH1
status and clinical outcome for the whole population (P
=. 1 0 ;F i g u r e2 A ,D ) .I nt h eg r o u po fp a t i e n t sa g e d
younger than 65 years, a strong association was found
between ALDH1 expression and poor clinical outcome
(P = .01; Figure 2B). In the subgroup of younger patients
who did not receive any systemic treatment, a compar-
able association was found (P = .009; Figure 2E). In this
group, 52% of patients with ALDH1-positive tumors was
relapse-free at 10 years follow-up compared to 72% of
patients with ALDH1-negative tumors (absolute differ-
ence = 20%). Conversely, in the elderly patients, no
association was found between ALDH1 status and clini-
cal outcome (P = .20; Figure 2C, F). Interaction analysis
demonstrated a statistically significant difference in the
prognostic effect of ALDH1 status in young and elderly
patients (P = .007).
Analysis of relative survival showed a similar pattern
as for relapse-free period: a strong association between
ALDH1-positive tumors and poor relative survival in the
younger patient group (Figure 3B, E) and no association
between ALDH1 status and relative survival for elderly
patients (Figure 3C, F). In the subgroup of younger
patients who did not receive any systemic treatment, the
10-year relative survival rate was 57% in patients with
ALDH1-positive tumors compared to 83% in patients
with ALDH1-negative tumors (absolute difference =
26%, P = .008; Figure 3E). Interaction analysis
Table 1 Association of ALDH1 status with clinicopathological charateristics, stratified by age*
Characteristic Patients < 65 years Patients > 65 years
ALDH1 negative ALDH1 positive ALDH1 negative ALDH1 positive
N%N%P N% N% P
Grade 0.02 0.79
I 19 17.3 18 8.5 11 12.9 13 16.2
II 58 52.7 103 48.6 44 51.8 38 47.5
III 33 30.0 91 42.9 30 35.3 29 36.2
Histological type 0.42 0.20
Ductal 103 92.8 191 90.1 72 84.7 73 91.2
Lobular 8 7.2 21 9.9 13 15.3 7 8.7
Tumor size 0.34 0.55
T1 45 40.2 74 36.1 27 31.0 24 31.6
T2 57 50.9 101 49.3 48 55.2 37 48.7
T3/4 10 8.9 30 14.6 12 13.8 15 19.7
Nodal status 0.02 0.71
Negative 69 62.2 101 47.9 46 56.1 46 59.0
Positive 42 37.8 110 52.1 36 43.9 32 41.0
ER status 0.61 0.01
Negative 43 41.0 91 44.0 16 19.0 30 38.0
Positive 62 59.0 116 56.0 68 81.0 49 62.0
PgR status 0.77 0.08
Negative 48 47.1 84 40.6 26 31.3 35 44.9
Positive 54 52.9 123 59.4 57 68.7 43 55.1
HER2 status 0.99 0.80
Negative 67 87.0 153 86.9 61 93.8 64 92.8
Positive 10 13.0 23 13.1 4 6.2 5 7.2
*Missing data not shown.
Abbreviations: N number of patients; ALDH1 aldehyde dehydrogenase 1; ER estrogen receptor; PgR progesterone receptor; HER2 human epidermal growth factor
receptor 2
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between the prognostic effect of ALDH1 status in young
and elderly patients (P = 0.047).
Multivariable analyses were conducted for the patient
groups that did not receive systemic treatment (276
young patients and 154 elderly patients). ALDH1 status
remained an independent prognostic factor in the young
patient group for both relapse-free period (hazard ratio
= 1.71; 95% CI, 1.09 to 2.68; P = .021; Table 2) and rela-
tive survival (relative excess risks of death = 2.36; 95%
CI, 1.22 to 3.68; P = .016; Table 3).
Discussion
In this study, we demonstrated that the presence of
ALDH1 expression is significantly higher in young
breast cancer patients than in elderly patients. More-
over, we demonstrated that ALDH1 expression is an
independent risk factor for decreased survival in
young breast cancer patients, but not in elderly
patients.
To the best of our knowledge, we are the first to show
that expression of ALDH1 in breast cancer is age-
dependent. A corresponding difference in the number of
cancer stem cells might provide an explanation for
known differences in clinical outcome between young
and elderly breast cancer patients. A potential strength
of our study is that it includes consecutive patients from
one center, not biased by being part of a clinical trial.
The age restriction of the majority of clinical trials pro-
hibits inclusion of patients older than 70 year and,
indeed, less than 10% of clinical trial participants is
older than 65 years [22]. In our study, 34% of patients
were 65 years or older at diagnosis of breast cancer.
Therefore, our study was not hampered by lack of statis-
tical power to analyse the effect of ALDH1 in the
elderly.
We showed that ALDH1 expression has a qualitative
age interaction effect. In our study, ALDH1 is a predic-
t o ro fp o o rp r o g n o s i si ny o u n gp a t i e n t s ,b u tA L D H 1
did not influence clinical outcome in elderly patients.
Recently, Zhou and colleagues pooled the available data
on the prognostic role of ALDH1 activity in breast can-
cer [18]. Their meta-analysis demonstrated that ALDH1
activity as assessed by immunohistochemistry was
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Figure 2 Relapse free period according to ALDH1 status for all patients (A, D), for patients aged < 65 years (B, E) and for patients
aged > 65 years (C, F); and for patients that received any or no systemic therapy (A-C) and for patients that did not receive systemic
therapy (D-F). Log-rank P-values are shown in each graph.
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Page 5 of 9significantly associated with worse overall survival (unad-
justed pooled relative risk, 2.83; 95% CI, 2.16 to 3.67; four
patient cohorts including 1,158 patients) [18]. However,
the authors did not stratify for age. In other studies, no
interaction was found between ALDH1 expression and
age [9,14,17]. However, in these studies, an age of 40 or
50 year was used as a cut-off for age stratification. We
used 65 years as a cut-off point as this may better match
with the bimodal age distribution of breast cancer, which
suggests that breast cancer may be characterized by
early- and late-onset tumor types with modes near ages
50 and 70 years [5,23]. As argued by Anderson et al.,
these modal ages do not suggest a sharp division of dis-
tinctive tumor categories, but rather reflect central ten-
dencies for the age distributions of biologically distinct
cancer populations [5,23]. In line with this bimodal age
distribution, a biological explanation of the qualitative
age-interaction of the prognostic effect of ALDH1
expression might be that of a changing micro-environ-
ment in elderly patients, which may result in hampered
signal transduction between tumor stem cells and the
micro-environment. Moreover, changes in metabolic pro-
cesses might limit the role of tumor stem cells in elderly
patients. Increasing evidence from the field of epigenetics
demonstrates that hypermethylation-induced repression
of genes required for stem cell differentiation is linearly
associated with age [24]. This suggests that, with increas-
ing age, the role of tumor stem cells becomes more lim-
ited. Notwithstanding the need to clarify the underlying
mechanism, this new finding on the age-dependent role
of ALDH1 activity warrants further validation and under-
lines the need of age stratification when assessing bio-
markers and new therapies for breast cancer patients.
A potential limitation of our study is the choice of
antibody that was used for immunohistochemical detec-
tion of ALDH1 expression, which is specific for the
ALDH1A1 isoform. This antibody has been generally
used in studies investigating the role of ALDH1 in
breast cancer patients [9,11,12,14]. In a recent study,
Marcato et al. investigated the expression of the differ-
ent ALDH1 isoforms in breast cancer stem cells, breast
cancer cell lines and fixed human breast cancer tissue

    
 	   
 


  		  
	 
	 
 
 

	  
 
 	  	  


(
0

)
+

(
)

,
0
,
-
 
'
#


-
+
 

-
'
 
(
-

&&*-# (-, 0 +, 0 +,

  
  	
	   		 
 
 	 
 	


 

 	 
 


 	 	
 	 
  	  


)

,
0
,
-
 
'
#


-
+
 

-
'
 
(
-

-+#,%
 ( "-#/ 
*),#-#/ 
-+#,%
 ( "-#/ 
*),#-#/ 
#".+ 	# )"( +.#$! -&
  
  
Figure 3 Relative survival according to ALDH1 status for all patients (A, D), for patients aged < 65 years (B, E) and for patients aged >
65 years (C, F); and for patients that received any or no systemic therapy (A-C) and for patients that did not receive systemic therapy
(D-F). Log-rank P-values are shown in each graph.
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Page 6 of 9using various techniques [25]. They found that
ALDH1A3 expression correlated better with ALDH1
activity and with tumor grade, metastasis and cancer
stage [25,26]. Therefore, future research studying breast
cancer stem cells should incorporate ALDH1A3 expres-
sion in order to determine its role as a potential marker
of cancer stem cell activity.
Conclusion
In conclusion, we demonstrated that expression of the
putative breast cancer stem cell marker ALDH1 and its
prognostic effect are age-dependent in breast cancer
patients. We demonstrate, for the first time, the differ-
ent prognostic impact of a molecular marker in elderly,
which suggests that fundamentally different biological
mechanisms underlie age-related breast cancer prog-
nosis. Our results support the hypothesis that breast
cancer biology of elderly patients and their younger
counterparts is distinct and emphasizes the importance
of analyzing and reporting age-specific effects in breast
cancer research.
Table 2 Univariate and multivariable analysis for relapses free period stratified by age for patients naive to systemic
treatment
Characteristic Patients < 65 years Patients > 65 years
Univariate analysis Multivariable analysis Univariate analysis Multivariable analysis
N HR 95% CI P HR 95% CI P N HR 95% CI P HR 95% CI P
Age .74
<4 0 3 3 1 0
40-50 98 1.10 0.62-1.96 0
50-60 101 1.29 0.73-2.29 0
> 60 44 1.29 0.66-2.52 154
Grade .03 0.21 .01 .29
I 3 11 1 2 41 1
II 131 1.45 0.76-2.75 1.06 0.40-2.78 74 1.73 0.66-4.58 1.30 0.48-3.58
III 75 2.17 1.12-4.20 1.54 0.58-4.11 44 3.66 1.39-9.61 2.01 0.70-5.75
Histological type .54 .53
Ductal 223 1 124 1
Other 15 1.24 0.63-2.45 18 0.74 0.30-1.87
Tumor stage < .001 0.05 .03 .90
pT1 137 1 1 59 1 1
pT2 109 1.66 1.16-2.37 1.60 1.01-2.55 71 2.23 1.22-4.09 1.16 0.56-2.40
pT3/4 22 2.73 1.57-4.76 2.04 1.07-3.88 18 2.11 0.82-5.45 1.23 0.42-3.63
Nodal stage < .001 < 0.001 < .001 < .001
Negative 204 1 1 109 1 1
Positive 69 4.25 3.02-5.99 4.44 2.89-6.82 36 3.94 2.28-6.82 3.33 1.77-6.24
ER status .59 .22
Negative 87 1 40 1
Positive 126 0.90 0.66-1.32 95 1.53 0.78-2.98
PgR status .78 .78
Negative 84 1 55 1
Positive 123 0.95 0.64-1.40 81 1.08 0.61-1.92
HER2 status .26 .05
Negative 143 1 105 1
Positive 19 1.44 0.76-2.71 4 0.05 0.00-23.3
ALDH1 status .01 0.02 .14
Negative 77 1 1 63 1
Positive 116 1.75 1.14-2.68 1.71 1.09-2.68 61 0.64 0.35-1.16
Abbreviations: N number of patients; HR hazard ratio; ER estrogen receptor; PgR progesterone receptor; HER2 human epidermal growth factor receptor 2; ALDH1
aldehyde dehydrogenase 1
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